Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Published:2018-02 Issue:10121 Volume:391 Page:659-667
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Wang Michael,Rule Simon,Zinzani Pier Luigi,Goy Andre,Casasnovas Olivier,Smith Stephen D,Damaj Gandhi,Doorduijn Jeanette,Lamy Thierry,Morschhauser Franck,Panizo Carlos,Shah Bijal,Davies Andrew,Eek Richard,Dupuis Jehan,Jacobsen Eric,Kater Arnon P,Le Gouill Steven,Oberic Lucie,Robak Taduesz,Covey Todd,Dua Richa,Hamdy Ahmed,Huang Xin,Izumi Raquel,Patel Priti,Rothbaum Wayne,Slatter J Greg,Jurczak Wojciech

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Mantle cell lymphoma;Cheah;J Clin Oncol,2016

2. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?;Dreyling;Haematologica,2016

3. Current approaches to mantle cell lymphoma: diagnosis, prognosis, and therapies;Cohen;Am Soc Clin Oncol Educ Book,2017

4. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med,2013

5. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy;Buggy;Int Rev Immunol,2012

Cited by 346 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

2. Dismantling relapsed/refractory mantle cell lymphoma;Blood Reviews;2024-09

3. Immune cell-mediated features of atherosclerosis;Frontiers in Cardiovascular Medicine;2024-08-21

4. Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation;Leukemia;2024-08-17

5. Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma;Expert Review of Hematology;2024-08-08